Hospital General Universitario De Albacete

The Hospital General Universitario De Albacete’s hematology department is focused on improving outcomes for patients with multiple myeloma, acute myeloid leukemia, and various lymphomas by testing innovative therapeutic regimens.

• Evaluation of new combination therapies for newly diagnosed multiple myeloma
• Assessment of targeted agents in relapsed or refractory acute myeloid leukemia
• Comparative studies of monoclonal antibodies versus standard chemotherapy in follicular lymphoma

Ongoing research aims to increase remission rates and reduce disease recurrence across these blood cancers.

Clinical trials at the site address both early‑stage and advanced breast cancer, exploring the balance between chemotherapy, endocrine therapy, and immunotherapy to personalize treatment.

• Determining the benefit of chemotherapy in node‑positive, hormone‑receptor‑positive, HER2‑negative disease with low recurrence scores
• Testing the addition of immune checkpoint inhibitors to standard chemotherapy in triple‑negative breast cancer
• Investigating strategies to manage diarrhoea associated with HER2‑targeted therapies

These studies seek to refine therapeutic decisions and improve quality of life for breast cancer patients.

Researchers are evaluating novel approaches for conditions such as multiple sclerosis, Huntington’s disease, and post‑COVID cognitive impairment, targeting disease progression and symptom relief.

• Comparing new oral agents to established treatments for relapsing multiple sclerosis
• Assessing the impact of metabolic modulators on cognitive decline in Huntington’s disease
• Testing herbal extracts for cognitive recovery after COVID‑19 infection

The goal is to slow disability progression and enhance daily functioning for patients with neurological disorders.

The hospital conducts trials aimed at reducing mortality and complications in acute cardiovascular and respiratory events, including acute respiratory distress syndrome and pulmonary embolism.

• Evaluating antiplatelet strategies after transcatheter aortic valve implantation
• Studying supplemental oxygen therapy for intermediate‑risk pulmonary embolism
• Investigating the safety of reduced‑dose anticoagulation in spontaneous coronary artery dissection

These investigations strive to optimize acute care protocols and improve long‑term outcomes.

A series of trials focus on improving management of allergic rhinitis, asthma, and related immune‑mediated conditions through both pharmacologic and allergen‑specific immunotherapy.

• Comparing sublingual versus subcutaneous grass pollen extracts for immunotherapy
• Assessing the efficacy of combined house‑dust‑mite extracts in patients with allergic rhinoconjunctivitis
• Evaluating the clinical benefit of grass and olive allergen immunotherapy using mobile‑app symptom tracking

The aim is to provide durable symptom relief and reduce reliance on rescue medications.

Specialized protocols are in place for rare diseases such as Langerhans Cell Histiocytosis and pediatric oncology, seeking to establish effective, low‑toxicity treatment pathways.

• Early switch to salvage therapy for multisystem LCH with risk‑organ involvement
• Intensified continuation therapy to prevent reactivation in single‑system LCH
• Investigating novel agents for pediatric acute lymphoblastic leukemia relapses

These studies aim to achieve disease resolution while minimizing long‑term sequelae.